Delfi Diagnostics Announces $225 Million Series B Financing To Develop Globally Accessible Portfolio Of Liquid Biopsy Tests
Delfi Diagnostics Announces $225 Million Series B Financing To Develop Globally Accessible Portfolio Of Liquid Biopsy Tests
07/18/22, 1:03 PM
Location
baltimore
Money raised
$225 million
Industry
biotechnology
Round Type
series b
Delfi Diagnostics, Inc., a pioneering developer of a new class of high-performance, accessible liquid biopsy tests for early cancer detection and monitoring, today announced a Series B funding of $225 million.
Company Info
Location
2809 boston street
baltimore, maryland, united states
Additional Info
DELFI Diagnostics is developing next-generation, blood-based tests that are accurate, accessible, and deliver a new way to help detect cancer. DELFI tests are built to solve the highest-burden population health issues, including in historically underserved demographics, and have the potential to save lives on a global scale. FirstLook Lung, for individuals eligible for lung cancer screening, is our first laboratory-developed screening test and requires a simple blood draw that can be incorporated with routine blood work. The test is based on fragmentomics, the discovery that cancer cells are more chaotic than normal cells and, when they die, leave behind tell-tale patterns and characteristics of cell-free DNA (cfDNA) fragments in the blood. The DELFI platform applies advanced machine-learning technology to whole-genome sequencing data to assess individuals' cfDNA fragments against populations with and without cancer. FirstLook Lung uses these millions of data points to reliably identify individuals who may have cancer detected through low-dose CT, including early-stage disease, with a negative predictive value of 99.8 percent. This test has not been cleared or approved by the FDA.